

	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	20 : 00
Hall Building	No.1 (Hall C 4F)	Symposium 1 Molecular Pathogenesis of Bone Marrow Failure Chairs : Toshio Kitamura, Atsushi Iwama			EHA Special Lecture Chair : Itaru Matsumura Speaker : Shai Izraeli	Opening Ceremony Presidential Lecture Special Lecture 1			Presidential Symposium 1			JSH Business Meeting	
	No.2 (Hall B7(1) 7F)	EL1-2A	EL1-2B	EL1-2C	LS1-2 Astellas Pharma Inc. / Amgen Astellas BioPharma K.K.			EL1-2D	EL1-2E	EL1-2F			
	No.3 (Hall B7(2) 7F)	EL1-3A	EL1-3B	EL1-3C	LS1-3 DAICHI SANKYO COMPANY, LIMITED			EL1-3D	EL1-3E	EL1-3F			
	No.4 (Hall B5(1) 5F)	Symposium 2 Iron Metabolism and Anemia: An Update Chairs : Takahiro Suzuki, Katsuya Ikuta			LS1-4 Pfizer Japan Inc.			Symposium 4					
	No.5 (Hall B5(2) 5F)	Symposium 3 Perspective on Targeted Molecular Therapy for Hematological Malignancy in Childhood Chairs : Atsushi Manabe, Shouichi Ohga			LS1-5 Nippon Shinyaku Co., Ltd.			Symposium 5 Germline Predisposition to MDS Chairs : Hironori Harada, Yasushi Miyazaki					
	No.6 (Hall D7 7F)	EL1-6A	EL1-6B	EL1-6C	LS1-6 Takeda Pharmaceutical Company			EL1-6D	EL1-6E	EL1-6F			
	No.7 (Hall D5 5F)	OS1-7A		OS1-7B		LS1-7 Novartis Pharma K.K.			OS1-7C		OS1-7D Multiple Myeloma: Novel Agents Chair : Chiaki Nakaseko		
	No.8 (Hall D1 1F)	OS1-8A		OS1-8B		LS1-8 AbbVie GK			OS1-8C		OS1-8D Hematopoietic Stem Cell (2) Chair : Kiyoshi Ando		
Glass Building	No.9 (G402 4F)	OS1-9A		OS1-9B		LS1-9 Accuray Japan K.K.			OS1-9C		OS1-9D Hemoglobinopathy Chair : Hitoshi Kanno		
	No.10 (G409 4F)	OS1-10A		OS1-10B		LS1-10 Sysmex Corporation / Novartis Pharma K.K.			OS1-10C		OS1-10D		
	No.11 (G502 5F)	OS1-11A Myeloid Neoplasms: Basic Chair : Takuro Kameda		OS1-11B		LS1-11 Sumitomo Dainippon Pharma Co., Ltd.			IS1-11 AbbVie GK		OS1-11C AML: Pathophysiology (1) Chair : Yoichi Imai		OS1-11D
	No.12 (G510 5F)	OS1-12A		OS1-12B ALL: Basic (2) Chair : Toshihiko Imamura		LS1-12 Meiji Seika Pharma Co., Ltd.			IS1-12 Alexion Pharma GK		OS1-12C		OS1-12D
	No.13 (G602 6F)	OS1-13A		OS1-13B		LS1-13 Janssen Pharmaceutical K.K.			OS1-13C		OS1-13D		
	No.14 (G610 6F)	OS1-14A Immune Cell Therapy Using iPS Cells Chair : Miki Ando		OS1-14B		LS1-14 Otsuka Pharmaceutical Co., Ltd.			OS1-14C		OS1-14D		
	No.15 (G701 7F)	OS1-15A		OS1-15B		LS1-15 Eisai Co., Ltd. / Symbio Pharmaceuticals			OS1-15C Multiple Myeloma: Clinical (1) Chair : Hiroshi Handa		OS1-15D		
	No.16 (G405 4F)	OS1-16A		OS1-16B		LS1-16 Sanofi K.K.			SETP 1 Thrombosis and Platelet Biolog				
	No.17 (G407 4F)	OS1-17A		OS1-17B Thrombosis and Hemostasis Chair : Kohei Tatsumi		LS1-17 Sanofi K.K.			SETP 2 Lymphoid Malignancies				
Hall E	Encore of Educational Lecture 1 (Seminar Room 1 B2F)		Encore of Educational Lecture 1										
	Encore of Educational Lecture 2 (Seminar Room 2 B2F)		Encore of Educational Lecture 2										
	Exhibition		Exhibition & Corporate Partner Lounge (9 : 00~18 : 50)										
	Poster		Poster Mounting (8 : 30~10 : 00)			Poster Viewing (10 : 00~17 : 40)					Poster Discussion (17 : 40~18 : 40)		Poster Removal (18 : 40~19 : 00)

**Day 2** Saturday, October 12 Tokyo International Forum

LS : Luncheon Seminar  
 MS : Morning Seminar  
 OS : Oral Session E Lectures in English

	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	20 : 00	
<b>Hall Building</b>	<b>No.1</b> (Hall C 4F)		<b>Presidential Symposium 2</b> A Fascinating Era for Myeloproliferative Neoplasms Chairs : Norio Komatsu, Yuzuru Kanakura			<b>ASH Special Lecture</b> Chair : Kimuko Mizani Speakers : Roy L Silverstein, Moua Yang	<b>Plenary Session</b> Chairs : Takanori Teshima, Akifumi Takaori-Kondo		<b>JSH-EHA Joint Symposium (Symposium 7)</b> MRD in AML Chairs : Shai Izraeli, Toshihiro Miyamoto			Mini Concert	Reception for all the participants (19 : 20~21 : 00)	
	<b>No.2</b> (Hall B7 (1) 7F)	<b>MS2-2</b> DAIICHI SANKYO COMPANY, LIMITED	EL2-2A	EL2-2B	EL2-2C		<b>LS2-2</b> Celgene K.K.		EL2-2D	EL2-2E	EL2-2F			
	<b>No.3</b> (Hall B7 (2) 7F)	<b>MS2-3</b> ONO PHARMACEUTICAL CO.,LTD.	Clinical Debate 1		Clinical Debate 2			<b>LS2-3</b> Janssen Pharmaceutical K.K.	Clinical Debate 3		Clinical Debate 4			
	<b>No.4</b> (Hall B5 (1) 5F)	<b>MS2-4</b> Amgen Astellas BioPharma K.K. Medical Affairs	EL2-4A	EL2-4B	EL2-4C		<b>LS2-4</b> Chugai Pharmaceutical Co., Ltd. / Nippon Shinyaku Co., Ltd		EL2-4D	EL2-4E	EL2-4F			
	<b>No.5</b> (Hall B5 (2) 5F)	<b>MS2-5</b> MSD K.K.	<b>Symposium 6</b> Aiming for Safer Transplants Chairs : Yoshihiro Inamoto, Ken-ichi Matsuoka				<b>LS2-5</b> Bristol-Myers Squibb K.K.	<b>Asian Joint Panel Discussion</b> Epidemiology, Diagnosis and Treatment of Myeloproliferative Neoplasms in Asian Countries Chairs : Yuzuru Shimoda, Dong-Tsamn Lin						
	<b>No.6</b> (Hall D7 7F)	<b>MS2-6</b> Celgene K.K.	EL2-6A	EL2-6B	EL2-6C		<b>LS2-6</b> Kyowa Kirin Co., Ltd.		EL2-6D	EL2-6E	EL2-6F			
	<b>No.7</b> (Hall D5 5F)	<b>MS2-7</b> CHUGAI PHARMACEUTICAL CO., LTD.	OS2-7A		OS2-7B			<b>LS2-7</b> Novartis Pharma K.K.	OS2-7C		OS2-7D			
	<b>No.8</b> (Hall D1 1F)	<b>MS2-8</b> Eisai Co., Ltd Medical HQs	OS2-8A		OS2-8B			<b>LS2-8</b> Alexion Pharma GK	OS2-8C		OS2-8D			
<b>Glass Building</b>	<b>No.9</b> (G402 4F)	<b>MS2-9</b> Sanofi K.K.	OS2-9A		OS2-9B			<b>LS2-9</b> PharmaEssentia Japan KK	<b>OS2-9C</b> Multiple Myeloma: Basic (Novel Molecular Targets) Chair : Yutaka Hattori		<b>OS2-9D</b> Multiple Myeloma: Clinical (Prognosis/Biomarker/Salvage Therapy) Chair : Chikako Ohwada			
	<b>No.10</b> (G409 4F)	<b>MS2-10</b> Takeda Pharmaceutical Company Limited	OS2-10A		OS2-10B			<b>LS2-10</b> Eisai Co., Ltd / Symbio Pharmaceuticals	OS2-10C		OS2-10D			
	<b>No.11</b> (G502 5F)	<b>MS2-11</b> Fuji Pharma Co., Ltd.	OS2-11A		OS2-11B			<b>LS2-11</b> Takeda Pharmaceutical Company Limited	<b>OS2-11C</b> CML: Basic (1) Chair : Yosuke Minami		OS2-11D			
	<b>No.12</b> (G510 5F)	<b>MS2-12</b> Novartis Pharma K.K.	OS2-12A		OS2-12B			<b>LS2-12</b> Novo Nordisk Pharma Ltd.	<b>OS2-12C</b> ALL: Clinical (3) Chair : Motohiro Kato		OS2-12D			
	<b>No.13</b> (G602 6F)	<b>MS2-13</b> Sanofi K.K.	<b>OS2-13A</b> MDS : Basic (1) Chair : Hirotaka Matsui		OS2-13B			<b>LS2-13</b> Fujimoto Pharmaceutical Corporation	<b>OS2-13C</b> MDS : Basic (2) Chair : Yuka Harada		OS2-13D			
	<b>No.14</b> (G610 6F)	<b>MS2-14</b> Bayer Yakuin, Ltd.	<b>OS2-14A</b> CART Therapy Chair : Ken Ohmine		OS2-14B			<b>LS2-14</b> Mundipharma K.K.	OS2-14C		OS2-14D			
	<b>No.15</b> (G701 7F)	<b>MS2-15</b> Janssen Pharmaceutical K.K., Medical Affairs Division	OS2-15A		OS2-15B			<b>LS2-15</b> Otsuka Pharmaceutical Co., Ltd.	OS2-15C		OS2-15D			
	<b>No.16</b> (G405 4F)		<b>Women Doctors Career Symposium</b>				<b>LS2-16</b> CSL Behring K.K.	<b>SETP 3</b> Immunotherapy and Precision Medicine						
	<b>No.17</b> (G407 4F)		OS2-17A		OS2-17B			<b>LS2-17</b> Pfizer Japan Inc.	<b>SETP 4</b> Myeloproliferative Neoplasms					
<b>Hall E</b>	<b>Encore of Educational Lecture 1</b> (Seminar Room 1 B2F)	<b>Encore of Educational Lecture 1</b>												
	<b>Encore of Educational Lecture 2</b> (Seminar Room 2 B2F)	<b>Encore of Educational Lecture 2</b>												
	<b>Exhibition</b>	<b>Exhibition &amp; Corporate Partner Lounge</b> (9 : 00~18 : 20)												
	<b>Poster</b>	<b>Poster Mounting</b> (8 : 30~10 : 00)			<b>Poster Viewing</b> (10 : 00~17 : 10)						<b>Poster Discussion</b> (17 : 10~18 : 20)		<b>Poster Removal</b> (18 : 20~19 : 00)	

	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	20 : 00	
Hall Building	No.1 (Hall C 4F)		JSH-ASH Joint Symposium (Symposium 8) Recent Advances in Translational and Clinical Research in Lymphoid Malignancies <small>Chairs : Roy Silverstein, Kunihiro Tsukasaki</small>			JSH Award Lecture	LS3-1 Novartis Pharma K.K.		Symposium 10 Novel Therapeutic Targets on the Surface of Myeloma Cells in Association with Marrow Microenvironment <small>Chairs : Yusuke Furukawa, Shinsuke Iida</small>					
	No.2 (Hall B7 (1) 7F)	MS3-2 Celgene K.K.	EL3-2A	EL3-2B	EL3-2C		LS3-2 Celgene K.K. Medical Affairs	Special Lecture 2 <small>Chair : Keiyo Ozawa</small>	EL3-2D	EL3-2E	EL3-2F			
	No.3 (Hall B7 (2) 7F)	MS3-3 Novartis Pharma K.K.	Clinical Debate 5		Clinical Debate 6		LS3-3 Astellas Pharma Inc.	Special Lecture 3 <small>Chair : Masahiro Kizaki</small>	Clinical Debate 7		Clinical Debate 8			
	No.4 (Hall B5 (1) 5F)	MS3-4 Gilead Sciences K.K.	EL3-4A	EL3-4B	EL3-4C		LS3-4 Pfizer Japan Inc.		EL3-4D	EL3-4E	EL3-4F			
	No.5 (Hall B5 (2) 5F)	MS3-5 Bristol-Myers Squibb K.K.	Symposium 9 Progress in Tumor Immunotherapy <small>Chairs : Kenzaburo Tani, Yoza Nakazawa</small>				LS3-5 ONO PHARMACEUTICAL CO., LTD. / Bristol-Myers Squibb K.K.	Public Symposium						
	No.6 (Hall D7 7F)	MS3-6 Astellas Pharma Inc. Medical Affairs	EL3-6A	EL3-6B	EL3-6C		LS3-6 Kyowa Kirin Co., Ltd.		EL3-6D	EL3-6E	EL3-6F			
	No.7 (Hall D5 5F)	MS3-7 CSL Behring K.K.	OS3-7A Multiple Myeloma: Daratumumab <small>Chair : Noriko Nishimura</small>		OS3-7B		LS3-7 PharmaEssentia Japan KK		OS3-7C	OS3-7D				
	No.8 (Hall D1 1F)	MS3-8 Zenyaku Kogyo Co., Ltd.	OS3-8A	OS3-8B			LS3-8 Eisai Co., Ltd / Symbio Pharmaceuticals		OS3-8C Hematopoietic Differentiation (1) <small>Chair : Keiyo Takubo</small>	OS3-8D				
Glass Building	No.9 (G402 4F)	MS3-9 Otsuka Pharmaceutical Co., Ltd.	OS3-9A	OS3-9B		LS3-9 Takeda Pharmaceutical Company Limited		OS3-9C Multiple Myeloma: Basic (Bone Metabolism/Biology) <small>Chair : Masahiro Abe</small>	OS3-9D					
	No.10 (G409 4F)	MS3-10 SHIONOGI & CO., LTD.	OS3-10A	OS3-10B		LS3-10 Janssen Pharmaceutical K.K., Medical Affairs Division		OS3-10C	OS3-10D					
	No.11 (G502 5F)	MS3-11 Asahi Kasei Pharma Corporation	OS3-11A	OS3-11B		LS3-11 CSL Behring K.K.		OS3-11C	OS3-11D					
	No.12 (G510 5F)	MS3-12 AstraZeneca K.K.	OS3-12A Genomic Mutation in AML <small>Chair : Yasuhito Nannya</small>	OS3-12B		LS3-12 MSD K.K.		OS3-12C	OS3-12D					
	No.13 (G602 6F)	MS3-13 MOCHIDA PHARMACEUTICAL CO., LTD.	OS3-13A	OS3-13B		LS3-13 Sanofi K.K.		OS3-13C	OS3-13D					
	No.14 (G610 6F)	MS3-14 Takeda Pharmaceutical Company Limited	OS3-14A GVHD (1) <small>Chair : Yoshiko Atsuta</small>	OS3-14B		LS3-14 AbbVie GK		OS3-14C	OS3-14D					
	No.15 (G701 7F)	MS3-15 Sumitomo Dainippon Pharma Co., Ltd.	OS3-15A Multiple Myeloma: Clinical (MRD/Infection) <small>Chair : Hiroyuki Takamatsu</small>	OS3-15B		LS3-15 Takeda Pharmaceutical Company Limited		OS3-15C AML: Genomic Analysis <small>Chair : Tetsuya Nosaka</small>	OS3-15D AML: Novel Therapy <small>Chair : Koichi Takahashi</small>					
Hall E	Encore of Educational Lecture 1 (Seminar Room 1 B2F)	Encore of Educational Lecture 1												
	Encore of Educational Lecture 2 (Seminar Room 2 B2F)	Encore of Educational Lecture 2												
	Exhibition	Exhibition & Corporate Partner Lounge <small>(9 : 00~16 : 00)</small>												
	Poster	Poster Mounting <small>(8 : 30~10 : 00)</small>	Poster Viewing <small>(10 : 00~13 : 20)</small>				Poster Discussion <small>(13 : 20~14 : 20)</small>	Poster Removal <small>(14 : 20~15 : 10)</small>						